Long-term Safety Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
a study on Peanut Allergy
- for people ages 4-55 (full criteria)
- at UCLA UCSF
- study startedestimated completion
Peanut Allergy AR101 Characterized Peanut Allergen OIT (oral immunotherapy) Allergy Peanut-Allergic Children Peanut-Allergic Adults Desensitization CPNA (Characterized Peanut Allergen) Hypersensitivity Peanut Hypersensitivity
- accepting new patients by invitation only
- Start Date
- Completion Date
- Aimmune Therapeutics, Inc.
- Click to request more information about this study.
- Phase 3
- Study Type
- Last Updated